Medicine
Kygevvi 2 g/2 g powder for oral solution
Kygevvi 2 g/2 g powder for oral solution is a prescription medicine containing Doxecitine and Doxribtimine for oral use, marketed by UCB, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store KYGEVVI packets at 20°C to 25°C (68°F to 77°F), excursion permitted…
Key facts
- Active ingredient (INN)
- Doxecitine and Doxribtimine
- Brand
- Kygevvi
- Strength
- 2 g/2 g
- Dosage form
- Powder for oral solution
- Route
- Oral
- Packs
- 30 packets
- Marketing authorisation holder
- UCB
- Manufacturer
- UCB
- Origin register
- US FDA, United States
- Storage
- Store KYGEVVI packets at 20°C to 25°C (68°F to 77°F), excursion permitted between 15°C to 30°C (59°F to 86°F). Store reconstituted KYGEVVI solution at controlled room temperature or in the refrigerator.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A16AX29 Doxecitine and Doxribtimine
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 1 March 2026
- Identifiers
- RxCUI 2737535, 2737541DailyMed set ID 7d5ce670-9314-4fd7-8b0a-1447910dcf9eNDC 50474-350Application NDA219792
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 30 packet in 1 carton / 1 powder, for solution in 1 packet | 50474-350-30 | UCB | 1 March 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Doxecitine and Doxribtimine is a fixed-dose combination medicine indicated for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with an age of symptom onset on or before 12 years. MedsAcross supplies Doxecitine and Doxribtimine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Doxecitine and DoxribtimineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- KYGEVVI prescribing information (UCB) · U.S. National Library of Medicine, DailyMed
- Kygevvi: European public assessment report (EPAR) · European Medicines Agency
Need Kygevvi 2 g/2 g powder for oral solution for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.